Posts

de-escalation and escalation treatment of early breast cancer—Interview with Giuseppe Curigliano at SGBCC 2023

surgery of the primary for stage IV disease—Interview with William Gradishar at SGBCC 2023

Do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)